Presentation is loading. Please wait.

Presentation is loading. Please wait.

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.

Published byLucas Carroll Modified over 6 years ago

Similar presentations

Presentation on theme: "Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara."— Presentation transcript:

1 Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, Alessandra Larocca, Thierry Facon, Shaji K. Kumar, Massimo Offidani, Philip McCarthy, Andrea Evangelista, Sagar Lonial, Sonja Zweegman, Pellegrino Musto, Evangelos Terpos, Andrew Belch, Roman Hajek, Heinz Ludwig, A. Keith Stewart, Philippe Moreau, Kenneth Anderson, Hermann Einsele, Brian G. M. Durie, Meletios A. Dimopoulos, Ola Landgren, Jesus F. San Miguel, Paul Richardson, Pieter Sonneveld, and S. Vincent Rajkumar Blood Volume 125(13): March 26, 2015 ©2015 by American Society of Hematology

2 Long-term outcomes. Long-term outcomes. (A) OS, (B) PFS, and (C) cumulative incidence of hematologic adverse events, (D) nonhematologic adverse events, and (E) discontinuation in the intention-to-treat population. Antonio Palumbo et al. Blood 2015;125: ©2015 by American Society of Hematology

Download ppt "Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara."

Similar presentations

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
Palumbo A et al. Proc ASH 2012;Abstract 446.

Palumbo A et al. Proc ASH 2012;Abstract 446.
1 National and Kapodistrian University of Athens, Athens, Greece; 2 Mayo Clinic, Scottsdale, AZ; 3 Division of Hematology, Mayo Clinic, Rochester, MN;

1 National and Kapodistrian University of Athens, Athens, Greece; 2 Mayo Clinic, Scottsdale, AZ; 3 Division of Hematology, Mayo Clinic, Rochester, MN;
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
EU Drug Approval and Reimbursement Policy

EU Drug Approval and Reimbursement Policy
Mateos MV et al. Proc ASH 2013;Abstract 403.

Mateos MV et al. Proc ASH 2013;Abstract 403.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.
How I treat extramedullary myeloma

How I treat extramedullary myeloma
CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Alternate designs for conduct and analysis of phase I cancer trials

Alternate designs for conduct and analysis of phase I cancer trials
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.
How I treat multiple myeloma in younger patients

How I treat multiple myeloma in younger patients

Similar presentations

Ads by Google